Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Hodgkin Disease 4Breast Neoplasms 4Leukemia, Myeloid, Acute 3Recurrence 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, B-Cell 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Biphenotypic, Acute 1Inflammatory Breast Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

Trastuzumab 3Paclitaxel 3Docetaxel 3Taxes 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tipifarnib 1romidepsin 1pertuzumab 1pegfilgrastim 1onvansertib 1neratinib 1grapiprant 1eribulin 1caficrestat 1Peripheral Blood Stem Cell Transplantation 1PF-05280014 1Ontruzant 1Ogivri 1Mesna 1Lapatinib 1Filgrastim 1Epirubicin 1Doxorubicin 1Depsipeptides 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inflammatory Breast Neoplasms × Mesna × Clear all
NCT00002627 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
30 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡